I am happy to collect at $5 in this very good compromise... come come come.... sell yours...... I am waiting...

Hahahaha......normal..,

Ai ya, these selling buying quee will disappear at 2:30 la

Congrats guys, for those who r still holding......going through the rock and roll last few weeks and I guess some can zzz soundly tonight....

https://www.theedgemarkets.com/article/six-questions-top-gloves-boss-he-announces-over-rm1b-quarterly-net-profit-today?fbclid=IwAR2Cubsi0drYTmlOUDhek6PkKFuDcNKlkplZNFSicIqkqiwe9labM3otx-E

KY has the rights over his opinions and of course we don’t need to bother if he is selling off his share...he sell off then only announce - the same thing when he buy....one of the good reasons that I found about TG buying is own share is they are holding too much cash at this time.. it has been determined that buybacks reduce the assets on the balance sheet, in this case - cash. As a result, ROA increases because assets are reduced and ROE increases because there is less outstanding equity. In general, the market views higher ROA and ROE as positives.

Reminder, mamak stall bukak till 2 am ya.....bagi yang tak boleh tidur malam ni....

Reminder, mamak stall bukak till 2 am ya.....bagi yang tak boleh tidur malam ni....

Wow, lagi 2 billion and more water blowing....manyak happy...mamak only bukak until 2am....just in case u cannot zzzzz.....

Wow, if really 1.72 bil, can u imagine what the share price/3 worth?

next month will be bigger than maybank....tan sri say...

live now...

Haha haha...hahahahahaha.....good things are coming.....

I heard someone say good news coming..TP 50 sen

Price already controlled by IB

‘Tis guy deserved a cucumber in his ass.....

Uncle, did u reload your gun? give an “A” if u did it....

Hahaha..fake news......cepat cepat reload your guns before getting wet

Don’t go in first..see first....many trap...just like EDUSPEC

Uncle didn’t tell u...actually he sold last time. And topping up now...

Anyhow, looking for 0.16-0.18 for new entry....

Ya, xoxo....I come to visit u in ICU....

Anyhow, it’s a psychology game in stock market...hope u all zzz well tonight...shining by next week...

Who didn’t zzzz well last night????

Haha haha......haha haha...sudah takut ka? No worry, it will be back.....

Up to them what they wanna write...we need to focus on fundamental...TG is still very strong....

Still hv a lots of local retailers selling....that’s y it’s drop...IB will keep collecting....until this end of the week la...

Prem....I know someone name Prem...he is a kaki pusing

Macquarie is talking about the future........they r fortune teller....

Macquarie report analyst the year 2022..they are talking about 2022....not now...

It should dipped below 7....

Listen listen......last round washing........still many panic retailers selling...get a bucket..sorry many bucket to trap the cheap tickets...
Good show next week....

Dow Jones and Nasdaq rebound

Dow Jones rebound

Malam jumaat 2.5 ya...

I tot 6.5 tomorrow

Day time watch movie...titanic movie, night time also watch movie.....

No worry, end of this year many countries will start to buy and implement vaccine to control the bug..no one care WHO.....this has been prolong too much long.....need to stop!!! Some countries beh tahan liao ...

Still waiting......below 20 sen

How many of u can’t zzz tonight?

Tomorrow down again......vaccine news still not enough to bring up this stock

Besok Ada turun lagi ka? Besok Ada turun baru Ada beli

today will go below 5..i think..... continue lau sai

GENEVA/BEIJING, Sept 8 (Reuters): The World Health Organisation is working with China on requirements for international approval of any Chinese Covid-19 vaccine, a senior official said on Monday (Sept 7).

"WHO's office in China and WHO headquarters has been working with the regulatory authorities in China," assistant director-general Mariangela Simao told a briefing in Geneva.

"We are in direct contact, we have been sharing information and the requirements for international approval of vaccines."

Chinese firm Sinovac Biotech Ltd said on Monday its coronavirus vaccine candidate appeared to be safe for older people, according to preliminary results from an early to mid-stage trial, while the immune responses triggered by the vaccine were slightly weaker than younger adults.

Health officials have been concerned about whether experimental vaccines could safely protect the elderly, whose immune systems usually react less robustly to vaccines, against the virus that has led to nearly 890,000 deaths worldwide.

Sinovac's candidate CoronaVac did not cause severe side effects in a combined Phase 1 and Phase 2 trials launched in May involving 421 participants aged at least 60, Liu Peicheng, Sinovac's media representative, told Reuters.

The complete results have not been published and were not made available to Reuters.

Four of the world's eight vaccines that are in the third phase of trials are from China.

For three groups of participants who respectively took two shots of low, medium and high-dose CoronaVac, over 90% of them experienced significant increase in antibody levels, while the levels were slightly lower than those seen in younger subjects but in line with expectation, Liu said in a statement.

CoronaVac, being tested in Brazil and Indonesia in the final-stage human trials to evaluate whether it is effective and safe enough to obtain regulatory approvals for mass use, has already been given to tens of thousands of people, including about 90% of Sinovac employees and their families, as part of China's emergency inoculation scheme to protect people facing high infection risk.

The extent of inoculations under the emergency programme, which China launched in July but has released few details about, points to how actively it is using experimental vaccines in the hopes of protecting essential workers against a potential Covid-19 resurgence, even as trials are still under way.

The potential vaccine could remain stable for up to three years in storage, Liu said, which might offer Sinovac some advantage in vaccine distribution to regions where cold-chain storage is not an option.

Such estimation is extrapolated from the fact that vaccines readings stayed within acceptable ranges for 42 days at 25 degrees Celsius, 28 days at 37C (98.6 F), and five months for 2-8C (35.6-46.4 F), Liu said, without disclosing complete data. - Reuters

WHO now working with China....

https://www.thestar.com.my/aseanplus/aseanplus-news/2020/09/08/who-working-with-china-on-requirements-for-covid-19-vaccine-approval?fbclid=IwAR078fd2A-6KcH96IcYgWctxyE_wvxRQ5Nzsvc8q5JAX18PbcdJLKy014lM

https://www.globaltimes.cn/content/1200192.shtml

Chinese military infectious disease expert Chen Wei said a COVID-19 vaccine her team produced can be effective against all existing mutations of the novel coronavirus, noting that they are preparing for mass vaccination at a low price whenever phase three clinical trial results come out.

"We have complete IP rights of this vaccine, which means we do not have to rely on others and can carry out our own research and development (R&D)," said Chen, an academician at the Chinese Academy of Engineering and a researcher at the Institute of Military Medicine under the Academy of Military Sciences, in an interview with Xinhua News Agency released on Monday.

She noted that "we can also allow Chinese people to get vaccinated at a low price whenever they need it."

The remarks came amid groundless reports from Western media claiming that China is stealing the US' research data on COVID-19 vaccines. Chinese medical experts rebutted the allegations and stressed that China is actually leading in COVID-19 vaccine R&D, not to mention that the two countries are focusing on different routes.

Undoubtedly China is among the first echelon in COVID-19 vaccine R&D as more than half of vaccines entering phase three clinical trials made public by the WHO are developed in China, Chen noted.

The vaccine Chen's team developed is a recombinant adenovirus vector vaccine named Ad5-nCoV. It is jointly developed by the team and Chinese biotech company CanSino Biologics Inc.

Tao Lina, a Shanghai-based immunological expert, estimated that Ad5-nCoV would probably be priced at 100 yuan ($14.64) per dose due to the lesser cost of the adenovirus vector vaccine compared to inactivated vaccines.

Some Chinese analysts also predicted that the price would not be too much higher than that of other respiratory infection vaccines - for example, the price of flu vaccines is roughly between 50-150 yuan in China - given the advantages of China's economic system as well as governmental support for major public health emergencies.

It is also possible that the vaccine would be offered to the public for free if there is another sudden outbreak in the country, analysts said.

Another Chinese vaccine producer the China National Biotec Group (CNBG), a Sinopharm unit, announced previously that two inactivated COVID-19 vaccines they produced would probably come onto the market by the end of December at a price of less than 1,000 yuan for two doses.

According to US media, the US federal government previously reached a deal with Pfizer and BioNTech to buy 100 million doses of their experimental vaccine candidate with $1.95 billion.

Ad5-nCoV was delivered into phase one clinical trials on March 16, making it the world's first COVID-19 candidate vaccine that entered clinical trials.

Dphar showing sign of rebound

Who ever brough this counter, sure win!!! Apa mahu takut....it will be back soon..see u at $6

I brough a litter bit high lately but I don’t takut takut.....this kind of drop is a favourite game of shark...TG poses a very strong fundamental....apa takut? Next week they will be back......